These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 3976729)

  • 41. Type III hyperlipoproteinemia: defective metabolism of an abnormal apolipoprotein E.
    Gregg RE; Zech LA; Schaefer EJ; Brewer HB
    Science; 1981 Feb; 211(4482):584-6. PubMed ID: 7455696
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of Cysteamine on Mutant ASL Proteins with Cysteine for Arginine Substitutions.
    Inauen C; Rüfenacht V; Pandey AV; Hu L; Blom H; Nuoffer JM; Häberle J
    Mol Diagn Ther; 2016 Apr; 20(2):125-33. PubMed ID: 26745957
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapy of cystinosis.
    Schneider JA
    N Engl J Med; 1985 Dec; 313(23):1473-4. PubMed ID: 4058550
    [No Abstract]   [Full Text] [Related]  

  • 44. [A case of apolipoprotein E3 deficiency (E2/2 phenotype) associated with renovascular hypertension and atherosclerosis obliterans].
    Chiao S; Nozaki S; Hara H; Nakajima T; Kameda K; Kubo M; Tokunaga K; Hirobe K; Matsuzawa Y; Tarui S
    Nihon Naika Gakkai Zasshi; 1984 Dec; 73(12):1805-10. PubMed ID: 6533213
    [No Abstract]   [Full Text] [Related]  

  • 45. Approval of cysteamine for patients with cystinosis.
    Schneider JA
    Pediatr Nephrol; 1995 Apr; 9(2):254. PubMed ID: 7794731
    [No Abstract]   [Full Text] [Related]  

  • 46. Cysteamine for cystinosis.
    Humphrey C
    Lancet; 1978 Nov; 2(8097):998. PubMed ID: 82025
    [No Abstract]   [Full Text] [Related]  

  • 47. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site.
    Weisgraber KH; Innerarity TL; Mahley RW
    J Biol Chem; 1982 Mar; 257(5):2518-21. PubMed ID: 6277903
    [No Abstract]   [Full Text] [Related]  

  • 48. Nephropathic cystinosis--a gap between developing and developed nations.
    Bertholet-Thomas A; Bacchetta J; Tasic V; Cochat P
    N Engl J Med; 2014 Apr; 370(14):1366-7. PubMed ID: 24693916
    [No Abstract]   [Full Text] [Related]  

  • 49. Cysteamine: an old drug with new potential.
    Besouw M; Masereeuw R; van den Heuvel L; Levtchenko E
    Drug Discov Today; 2013 Aug; 18(15-16):785-92. PubMed ID: 23416144
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Apolipoprotein E to B ratio: a marker for type III hyperlipoproteinaemia.
    März W; Feussner G; Siekmeier R; Donnerhak B; Schaaf L; Ruzicka V; Gross W
    Eur J Clin Chem Clin Biochem; 1993 Nov; 31(11):743-7. PubMed ID: 8305617
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunological discrimination between the human apolipoprotein E2(Arg158----Cys) and E3 isoforms.
    Gerritse K; de Knijff P; van Ierssel G; Havekes LM; Frants RR; Schellekens MM; Zegers ND; Claassen E; Boersma WJ
    J Lipid Res; 1992 Feb; 33(2):273-80. PubMed ID: 1373757
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cysteamine inhibition of [15N]-glycine turnover in cystinosis and of glycine cleavage system in vitro.
    Yudkoff M; Nissim I; Schneider A; Segal S
    Metabolism; 1981 Nov; 30(11):1096-103. PubMed ID: 7289883
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neurocognitive Complications of Cystinosis.
    Trauner D
    J Pediatr; 2017 Apr; 183S():S15-S18. PubMed ID: 28343470
    [No Abstract]   [Full Text] [Related]  

  • 54. Results of the study of apolipoprotein E and its isomorphs on isoelectric focusing in dyslipoproteinemias.
    Bruckert E; Dairou F; de Gennes JL; Truffert J; Luc G
    Adv Exp Med Biol; 1987; 210():47-53. PubMed ID: 3591556
    [No Abstract]   [Full Text] [Related]  

  • 55. From the National Institutes of Health.
    Raub W
    JAMA; 1990 Oct; 264(13):1650. PubMed ID: 2398599
    [No Abstract]   [Full Text] [Related]  

  • 56. Access to Orphan Drugs is a Challenge for Sustainable Management of Cystinosis in China.
    Li XQ; Peng XX; Gong CX
    Chin Med J (Engl); 2018 Oct; 131(19):2388-2389. PubMed ID: 30246737
    [No Abstract]   [Full Text] [Related]  

  • 57. Cysteamine in treatment of type III hyperlipidaemia?
    Fisher EA; Gahl WA
    Lancet; 1982 Nov; 2(8308):1131-2. PubMed ID: 6128453
    [No Abstract]   [Full Text] [Related]  

  • 58. Standardized determination of apolipoprotein E phenotypes by simplified isoelectric focusing/immunoblotting in plasma and synovial fluid.
    Adiloglu AK; Gurakur-Osborne A; Prete PE
    Clin Chim Acta; 1998 May; 273(1):99-102. PubMed ID: 9620475
    [No Abstract]   [Full Text] [Related]  

  • 59. Cysteamine assay for the evaluation of bioactive electrophiles.
    Novák D; Vrba J; Zatloukalová M; Roubalová L; Stolarczyk K; Dorčák V; Vacek J
    Free Radic Biol Med; 2021 Feb; 164():381-389. PubMed ID: 33429019
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The use of CDME in cystinosis research.
    Wilmer MJ; van den Heuvel LP; Levtchenko EN
    Neurochem Res; 2008 Nov; 33(11):2373-4. PubMed ID: 18427982
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.